Primary hyperhidrosis of the axillae

Active Ingredient: Botulinum toxin type A

Indication for Botulinum toxin type A

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Botulinum toxin type A is indicated for the management of severe hyperhidrosis of the axillae, which does not respond to topical treatment with antiperspirants or antihidrotics.

For this indication, competent medicine agencies globally authorize below treatments:

50 Units to each axilla once every 16 weeks


Dosage regimens

Intradermal, 50 international units botulinum toxin type A, once every 16 weeks.

Detailed description

Recommended needle: Sterile 30 gauge needle.

Administration guidance: The hyperhidrotic area to be injected may be defined by using standard staining techniques, e.g. Minorยดs iodine-starch test.

Recommended dose: 50 Units of botulinum toxin type A is injected intradermally to each axilla, evenly distributed in multiple sites approximately 1-2 cm apart.

The recommended injection volume for intradermal injection is 0.1-0.2 ml.

Maximum dose: Doses other than 50 Units per axilla cannot be recommended.

Additional information: Clinical improvement generally occurs within the first week after injection and persists for 4-7 months.

Repeat injection of botulinum toxin type A can be administered when the clinical effect of a previous injection diminishes and the treating physician deems it necessary. Injections should not be repeated more frequently than every 16 weeks.

Dosage considerations

The maximum cumulative dose should not exceed 400 Units in a 12-week interval.

Active ingredient

Botulinum toxin type A

Botulinum toxin type A is a protein complex derived from Clostridium botulinum. The protein consists of type A neurotoxin and several other proteins. Under physiological conditions it is presumed that the complex dissociates and releases the pure neurotoxin. Intramuscular injection of the neurotoxin complex blocks cholinergic transport at the neuromuscular junction by preventing the release of acetylcholine. The nerve endings of the neuromuscular junction no longer respond to nerve impulses and secretion of the chemotransmitter is prevented (chemical denervation).

Read more about Botulinum toxin type A

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.